Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.

[1]  L. Allen,et al.  Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[2]  K. Paschke,et al.  DILATED CARDIOMYOPATHY AND ATRIAL ARRHYTHMIA IN A PATIENT WITH A PRIOR REPAIRED ATRIAL SEPTAL DEFECT: DON'T LET THE HISTORY FOOL YOU , 2019, Journal of the American College of Cardiology.

[3]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[4]  T. Biering-Sørensen,et al.  Left ventricular ejection time is an independent predictor of incident heart failure in a community‐based cohort , 2018, European journal of heart failure.

[5]  S. Solomon,et al.  Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. , 2018, JACC. Heart failure.

[6]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[7]  M. Metra,et al.  Heart failure , 2017, The Lancet.

[8]  V. J. Planelles-Herrero,et al.  Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil , 2017, Nature Communications.

[9]  J. Teerlink,et al.  Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. , 2017, Handbook of experimental pharmacology.

[10]  Piotr Ponikowski,et al.  Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial , 2016, The Lancet.

[11]  S. Solomon,et al.  The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF) , 2016 .

[12]  T. Bányász,et al.  Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes. , 2016, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[13]  S. Solomon,et al.  Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.

[14]  S. Solomon,et al.  Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.

[15]  Piotr Ponikowski,et al.  Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. , 2016, Journal of the American College of Cardiology.

[16]  C. Banfield,et al.  Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects , 2015, International journal of clinical pharmacology and therapeutics.

[17]  B. Greenberg,et al.  Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. , 2015, JACC. Heart failure.

[18]  M. V. van Dieijen-Visser,et al.  Circulating cardiac troponin T exhibits a diurnal rhythm. , 2014, Journal of the American College of Cardiology.

[19]  B. Morgan,et al.  Cardiac myosin activation part 1: from concept to clinic. , 2011, Journal of molecular and cellular cardiology.

[20]  J. Goldman,et al.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study , 2011, The Lancet.

[21]  J. Cleland,et al.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.

[22]  D. Cox,et al.  Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.

[23]  Whitney W. Smith,et al.  Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. , 2010, ACS medicinal chemistry letters.

[24]  T. Trikalinos,et al.  Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. , 2010, Journal of the American College of Cardiology.

[25]  K. George,et al.  Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. , 2010, Journal of the American College of Cardiology.

[26]  S. Vatner,et al.  Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure , 2010, Circulation. Heart failure.

[27]  J. Butler,et al.  Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge , 2004 .

[28]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[29]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[30]  A. Weissler,et al.  Systolic Time Intervals in Heart Failure in Man , 1968, Circulation.